OXIS International announces plans to Enter the Cannabis Biotech Sector, Completion of Financing, Changes to the Board of

PR Newswire/Les Echos/ 
OxIS International announces plans to Enter the Cannabis Biotech Sector, 
     Completion of Financing, Changes to the Board of Directors 
Oxis International, Inc. (OXI.PA) announced company management has changed the
business and plans to enter the cannabis biotech space. To support the change 
of business, the company completed a $1.425 million financing. Mr. Anthony 
Cataldo has joined the OXIS Board of Directors and will serve as Chairman of 
the Board. 
BEVERLY HILLS, California, Aug. 11, 2014 -- Oxis International, Inc. (OXI.PA)
announced today company management has changed the business and plans to enter
the cannabis biotech space. To support the change of business, the company
completed a $1.425 million financing. Mr. Anthony Cataldo has joined the OXIS
Board of Directors and will serve as Chairman of the Board. 
The changing landscape of medical marijuana laws sweeping the nation has 
created incredible opportunities for commercialization of cannabis related 
therapies. (OXI.PA) management team is currently in discussions to license 
certain intellectual property from some of the world's foremost authorities in 
the cannabis space. The just completed financing of $1.425 million will be used
to bring the company's required SEC filings to current status, increase 
marketing of OXIS nutraceutical products, and investigate possible business 
acquisitions in the nutraceutical and/or marijuana sector. 
As part of the change of business direction, directors Anshuman Dube and David
Saloff have resigned from the Board of Directors. Mr. Anthony Cataldo has been
appointed to the Board and will serve as Chairman. Mr. Cataldo has an extensive
career in the biotech industry including most recently as Chairman and CEO of
Genesis Biopharma , now Lion BIotechnologies Inc. (LBIO), where he was
responsible for the acquisition of licenses and CRADA for various cancers
utilizing T-cell therapy from the National Cancer Institute. 
OXIS CEO Kenneth Eaton stated, "We are very excited about our new direction at
OXIS. The cannabis industry provides our shareholders many opportunities that
simply did not exist before. Our team at OXIS is uniquely positioned to take
advantage of this new business sector." 
Forward-Looking Statements Except for historical information contained herein,
the statements in this release are forward-looking and made pursuant to the 
safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are inherently unreliable and actual results may
differ materially. Examples of forward-looking statements in this news release
include statements regarding the payment of dividends, marketing and
distribution plans, development activities and anticipated operating results.
Factors which could cause actual results to differ materially from these
forward-looking statements include such factors as the Company's ability to
accomplish its business initiatives, significant fluctuations in marketing
expenses and ability to achieve and expand significant levels of revenues, or
recognize net income, from the sale of its products and services, as well as 
the introduction of competing products, or management's ability to attract and
maintain qualified personnel necessary for the development and 
commercialization of its planned products, and other information that may be 
detailed from time to time in the Company's filings with the United States 
Securities and Exchange Commission. The Company undertakes no obligation to 
publicly update or revise any forward-looking statements, whether as a result 
of new information, future events or otherwise. 
CONTACT: Jonathan Barkman, Riverview Capital Enterprises, 1275 Glenlivet Dr Ste
100, Allentown, PA 18106, office 866-845-0105, fax 484-224-2999
 

SOURCE Oxis International, Inc. 
                  
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Aug/11/2014 05:54 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.